Table 3.
Univariate and multivariate analyses for overall survival
| Characteristics | Values (n = 1187), n (%) | Overall survival |
|||
|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Bone | |||||
| No | 1146 (97) | 1 | <0.001 | 1 | <0.001 |
| Yes | 41 (3) | 2.04 (1.46-2.87) | 2.24 (1.54-3.26) | ||
| Arm | |||||
| Doublet + Bev | 596 (50) | 1 | 0.007 | 1 | 0.037a |
| FOLFOXIRI + Bev | 591 (50) | 0.83 (0.72-0.95) | 0.85 (0.73-0.99) | ||
| Age, years | |||||
| <70 | 1005 (85) | 1 | 0.107a | — | — |
| ≥70 | 182 (15) | 1.16 (0.97-1.40) | — | ||
| ECOG PS | |||||
| 0 | 1038 (87) | 1 | <0.001 | 1 | <0.001 |
| 1-2 | 149 (13) | 2.24 (1.86-2.70) | 2.14 (1.75-2.62) | ||
| Sex | |||||
| Female | 494 (42) | 1 | 0.180a | — | — |
| Male | 693 (58) | 1.10 (0.96-1.26) | — | ||
| Previous adjuvant therapy | |||||
| No | 1108 (93) | 1 | <0.001 | 1 | 0.357 |
| Yes | 79 (7) | 0.57 (0.42-0.77) | 0.82 (0.53-1.26) | ||
| Time to metastases | |||||
| Metachronous | 179 (15) | 1 | <0.001 | 1 | 0.312 |
| Synchronous | 1008 (85) | 1.53 (1.24-1.87) | 1.16 (0.87-1.55) | ||
| Resected primary tumor | |||||
| No | 499 (42) | 1 | <0.001 | 1 | 0.002 |
| Yes | 688 (58) | 0.70 (0.61-0.80) | 0.77 (0.66-0.91) | ||
| Site of primary tumor | |||||
| Right | 408 (34) | 1 | <0.001 | 1 | 0.002 |
| Left and rectum | 751 (64) | 0.74 (0.64-0.85) | 0.83 (0.71-0.98) | ||
| Unknown | 28 (2) | — | — | ||
| Mutational status | |||||
| All WT | 237 (20) | 1 | 1 | ||
| RAS mut | 672 (57) | 1.65 (1.37-2.00) | <0.001a | 1.64 (1.35-2.00) | <0.001a |
| BRAF mut | 94 (8) | 2.96 (2.24-3.92) | <0.001a | 2.85 (2.12-3.83) | <0.001a |
| Unknown | 184 (15) | — | — | ||
Bold values are significant P values.
a
Non-significant P values.